A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma

Background: Combination treatment with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has been widely used in patients with unresectable hepatocellular carcinoma (uHCC). As no standard guidelines exist for second-line therapy after failure of combination treatment, this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Renguo, Yu, Chengyou, Li, Shaohua, Mei, Jie, Wei, Wei, Guo, Rongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561133/
https://www.ncbi.nlm.nih.gov/pubmed/36249812
http://dx.doi.org/10.3389/fphar.2022.998534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561133/
https://www.ncbi.nlm.nih.gov/pubmed/36249812
http://dx.doi.org/10.3389/fphar.2022.998534

Ejemplares similares